Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Agarwal, Kosh ^{[3
]}

Chan, Henry Ly ^{[4
]}

Seto, Wai-Kay ^{[5
,6
]}

Lim, Young-Suk ^{[7
]}

Brunetto, Maurizia ^{[8
]}

Chuang, Wan-Long ^{[9
]}

Janssen, Harry ^{[10
,11
]}

Fung, Scott ^{[12
]}

Izumi, Namiki ^{[13
]}

Jablkowski, Maciej ^{[14
]}

Abramov, Frida ^{[15
]}

Wang, Hongyuan ^{[15
]}

Yee, Leland ^{[15
]}

Mateo, Roberto ^{[15
]}

Flaherty, John F. ^{[15
]}

Pan, Calvin ^{[16
]}

Shalimar ^{[17
]}

Marcellin, Patrick ^{[18
]}

Gane, Edward J. ^{[19
]}

机构：

[1] Hosp Univ Vall dHebron, Barcelona, Spain

[2] CIBEREHD Inst Carlos III, Madrid, Spain

[3] Kings Coll Hosp NHS Fdn Trust, Inst Liver Studies, London, England

[4] Chinese Univ Hong Kong, 9F Union Hosp, HMA Off, Tai Wai, Hong Kong, Peoples R China

[5] Univ Hong Kong, Dept Med, Pok Fu Lam, Hong Kong, Peoples R China

[6] Univ Hong Kong, Sch Clin Med, Pok Fu Lam, Hong Kong, Peoples R China

[7] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[8] Azienda Osped Univ Pisana, Pisa, Italy

[9] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[10] Univ Hlth Network, Toronto Ctr Liver Dis, Toronto, ON, Canada

[11] Erasmus MC, Rotterdam, Netherlands

[12] Univ Toronto, Dept Med, Toronto, ON, Canada

[13] Japanese Red Cross Musashino Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[14] Med Univ Lodz, Lodz, Poland

[15] Gilead Sci Inc, Foster City, CA USA

[16] New York Univ, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[17] All India Inst Med Sci, New Delhi, India

[18] Hop Beaujon, Hepatol Dept, Clichy, France

[19] Auckland Clin Studies, Symonds St, Auckland, New Zealand

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OS-067

引用

页码：S57 / S57

页数：1

共 50 条

[31] A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
Brunetto, M.
Lim, Y. S.
Gane, E.
Seto, W. K.
Osipenko, M.
Ahn, S. H.
Janssen, H. L.
Shukla, A.
Chuang, W. L.
Trinh, H.
Celen, M. K.
Flaherty, J. F.
Lau, A. H.
Gaggar, A.
Suri, V.
Bhardwaj, N.
Kim, K.
Subramanian, G. M.
Pan, C.
Izumi, N.
Marcellin, P.
Chan, H.
Buti, M.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S26
[32] A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-NEGATIVE, CHRONIC HEPATITIS B: WEEK 48 EFFICACY AND SAFETY RESULTS
Buti, M.
Gane, E.
Seto, W. K.
Chan, H. L. Y.
Chuang, W. -L.
Stepanova, T.
Hui, A. J.
Lim, Y. -S.
Mehta, R.
Janssen, H. L. A.
Acharya, S. K.
Flaherty, J. F.
Massetto, B.
Cathcart, A.
Dinh, P.
Subramanian, G. M.
McHutchison, J. G.
Pan, C.
Brunetto, M.
Izumi, N.
Marcellin, P.
JOURNAL OF HEPATOLOGY, 2016, 64 : S135 - S136
[33] Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up
van Campenhout, Margo J. H.
Brouwer, Willem Pieter
Xie, Qing
Guo, S.
Chi, Heng
Qi, Xun
Tabak, Fehmi
Streinu-Cercel, Adrian
Wang, Ji-Yao
Zhang, Ning-Ping
Idilman, Ramazan
Reesink, Hendrik W.
Diculescu, Mircea
Simon, Krzysztof
Akdogan, Meral
Mazur, Wlodzimierz
de Knegt, Rob J.
Verhey, Elke
Hansen, Bettina E.
Janssen, Harry L. A.
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (01) : 109 - 117
[34] Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B
Nishikawa, Tomohiro
Matsui, Masahiro
Onishi, Saori
Ushiro, Kosuke
Asai, Akira
Kim, Soo-Ki
Nishikawa, Hiroki
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
[35] The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
Lacey, L. F.
Gane, E.
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (11) : 751 - 766
[36] Efficacy of long-term lamivudine therapy in HBeAg negative chronic hepatitis B
Dimou, E
Papatheodoridis, GC
Laras, A
Rapti, I
Dourakis, S
Hadziyannis, SJ
HEPATOLOGY, 1999, 30 (04) : 646A - 646A
[37] Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b
Buster, Erik H. C. J.
Flink, Hajo J.
Cakaloglu, Yilmaz
Simon, Krzysztof
Trojan, Joerg
Tabak, Fehmi
So, Thomas M. K.
Feinman, S. Victor
Mach, Tomasz
Akarca, Ulus S.
Schutten, Martin
Tielemans, Wanda
van Vuuren, Anneke J.
Hansen, Bettina E.
Janssen, Harry L. A.
GASTROENTEROLOGY, 2008, 135 (02) : 459 - 467
[38] Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients - authors' reply
Yaghoobi, M.
Yuan, Y.
Hunt, R. H.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (09) : 993 - 993
[39] Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
Long, Jianfei
Gong, Jingru
Zhu, Han
Liu, Xiaolin
Li, Ling
Chen, Bicui
Ren, Hongyan
Liu, Chao
Lu, Huiping
Zhang, Jiming
Wang, Bin
FRONTIERS IN MICROBIOLOGY, 2023, 14
[40] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety results
Strasser, S.
Roberts, S.
Angus, P.
Chan, H. L. Y.
Fung, S.
Seto, W. K.
Chuang, W. L.
Chen, C. Y.
Kim, H. J.
Hui, A. J.
Janssen, H. L. A.
Chowdhury, A.
Tsang, T. Y. O.
Mehta, R.
Gane, E.
Flaherty, J. F.
Massetto, B.
Kitrinos, K.
Dinh, P.
Subramanian, G. M.
Mchutchison, J. G.
Lim, Y. S.
Acharya, S. K.
Agarwal, K.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 82 - 82

← 1 2 3 4 5 →